

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7096615
<b>Application Number:</b>	10575894
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4681
<b>Title of Invention:</b>	Cancer gene therapeutic drug
<b>First Named Inventor/Applicant Name:</b>	Katsuyuki Hamada
<b>Customer Number:</b>	01609
<b>Filer:</b>	Mark Andrew Hissong
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	56939
<b>Receipt Date:</b>	26-FEB-2010
<b>Filing Date:</b>	14-APR-2006
<b>Time Stamp:</b>	13:35:05
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	10507
Deposit Account	
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	------------------	------------------

1	Transmittal Letter	56939_IDS_LETTER_2_26_10.pdf	22866 c713333c15e65c3cf2cde7225763902478de7b68	no	1
Warnings:					
Information:					
2	NPL Documents	56939_NPL_Ref_Blood.pdf	2324014 c7ad1ecf3f36be9a850c29ac817b5d3263879c27	no	10
Warnings:					
Information:					
3	NPL Documents	56939_NPL_Ref_Gene_Therapy.pdf	3151363 17e890bd6bcb5ea9bc60b25f12caa0640e83a20	no	22
Warnings:					
Information:					
4	NPL Documents	56939_NPL_Ref_Genomics.pdf	1448603 685144fbfe6f12322f7370b93aad398fe353507f	no	8
Warnings:					
Information:					
5	NPL Documents	56939_NPL_Ref_Human_Gene_Therapy.pdf	1850806 24d5711d155496caab505f86c6cc725fb7fb9860	no	11
Warnings:					
Information:					
6	NPL Documents	56939_NPL_Ref_JVirol.pdf	1721627 e67e4f59268d800e824dd4a8bdcab72a7b291854	no	9
Warnings:					
Information:					
7	NPL Documents	56939_NPL_Ref_Nature_Medicine.pdf	1592064 5bf77b12d8fdbfe17cfa3f457ce6a26e13816092	no	7
Warnings:					
Information:					
8	Information Disclosure Statement (IDS) Filed (SB/08)	56939_SB08a_2_26_10.pdf	34227 edfffa252622a358e408d9f8e8240bedcbe7ca81	no	4
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
9	Fee Worksheet (PTO-875)	fee-info.pdf	30016 03086b136798398cf975ebc92ed2648b9bc6f570	no	2

<b>Warnings:</b>	
<b>Information:</b>	
<b>Total Files Size (in bytes):</b>	12175586
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>	